The previously mentioned CAF subtype expressing inflammatory factors in melanoma inhibited immune-checkpoint blockade (ICB) therapy response, and CAF-secreted CXCL12 contributed to tumor progression and gemcitabine resistance via upregulating SATB-1 secretion [91, 146]. The gene discussed is CXCL12; the disease is neoplasm.